NEW YORK (
) -- Shares of
) were gapping down Thursday morning with an open price 14.1% lower than Wednesday's closing price. The stock closed at $14.10 Wednesday and opened today's trading at $12.11.
The average volume for Alkermes has been 671,400 shares per day over the past 30 days. Alkermes has a market cap of $1.3 billion and is part of the
industry. Shares are up 14.8% year to date as of the close of trading on Wednesday.
Alkermes, Inc., an integrated biotechnology company, provides extended-release injectable and oral products for the treatment of prevalent and chronic diseases, such as central nervous system disorders, reward disorders, addiction, diabetes, and autoimmune disorders.
TheStreet Ratings rates Alkermes as hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full
Get more investment ideas from our